This is a working overview of TB-500, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-18. Anything still debated is marked as such rather than presented as settled.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
There are mainly two methods for loading samples onto FD emitters: the emitter-dipping technique and the syringe technique. Emitter-dipping technique is simple and commonly used in most laboratories. In this technique, the solid samples are dissolved or suspended in a suitable medium, and then an activated emitter (usually a tungsten wire with many microneedles) is dipped into the solution and drawn out again. When the wire is removed from the solution, the solution of a volume about 10−2 μL adheres to the microneedles (an average length of 30 μm) or remains between them. The other technique, syringe technique, applies to the compounds which are less concentrated than 10−5 M. A droplet of the solution from a microsyringe which is fitted to a micromanipulator is deposited uniformly on the microneedles. After evaporation of the solvent, the procedure for the two techniques can be repeated several times to load more samples. The syringe technique has the advantage that measured volumes of the solution can be accurately dispensed on the center of the wire.
=== Dispute with Vivendi === On September 20, 2004, GameSpot reported that Sierra's parent company, Vivendi Universal Games, was in a legal battle with Valve over the distribution of Half-Life 2 to cyber cafés. Cyber cafés were important for the gaming market in Asia, where PC and broadband penetration per capita were much lower in most territories. According to Vivendi, the distribution contract they signed with Valve included cyber cafés. This would mean that only Vivendi could distribute Half-Life 2 to cyber cafés — not Valve through the Steam system. On November 29, 2004, Judge Thomas S. Zilly, of U.S. Federal District Court in Seattle, Washington, ruled that Vivendi and its affiliates were not authorized to distribute (directly or indirectly) Valve games through cyber cafés for pay-to-play activities according to the parties' current publishing agreement. Zilly also ruled in favor of the Valve motion regarding the contractual limitation of liability, allowing Valve to recover copyright damages for any infringement as allowed by law without regard to the publishing agreement's limitation of liability clause. On April 29, 2005, Valve and Vivendi announced a settlement. Vivendi would cease distributing all retail packaged versions of Valve games by August 31, 2005. Vivendi was also to notify distributors and cyber cafés that had been licensed by Vivendi that only Valve had the authority to distribute cyber café licenses; their licenses were revoked and switched to Valve's.
== Actinide partitioning: complexation mechanism == The selective separation of actinides from the PUREX raffinate by advanced processes needs new extracting agents, which must possess a more pronounced affinity towards actinides over lanthanides and other products mostly present in the acidic fuel dissolution. The design and the synthesis of efficient extracting agents rely on a deep knowledge of the complexation mechanism involved in the extraction process. Moreover, the structure and the stability of the ligand complexes with An(III) and Ln(III) upon extraction process, and the ligand selectivity need to be investigated. Research is being devoted to design more N-donor extracting agents, which show promising selectivity towards actinides.
=== Indigenous Affairs === In the April 2019 budget, funding for the Ministry of Indigenous Affairs was cut in half. Minister Rickford released a May 9, 2019 statement saying that the Ontario Government was "committed to do everything in its authority to support the relocation" of the Kashechewan First Nation. which is located north of Fort Albany, Ontario on the James Bay coast. The community has had flooding and infrastructure problems for many years and in April 2019, had to evacuate 2,500 members by plane when a state of emergency was called again. APTN reported, in the presence of 300 community members, both the federal and provincial governments signed the Framework Agreement with Kashechewan First Nation to commit to moving the reserve. The federal Minister of Indigenous Services Seamus O'Regan said the relocation process would probably take about eight years to complete.
== Method principle == Before the introduction of the first automated cell counters, hematologists were referred to manual cell count under the microscope. The Celloscope method for automated counting of blood cells was described in an article by Öhlin in 1958. In the described method, cells in a saline (conductive) solution are allowed to pass through a capillary with a length and diameter corresponding to the size of blood cells. At the same time, an electric current passes the capillary, and each cell then gives rise to an electric pulse through the increase in resistance that it causes in the electric circuit. The number of pulses is recorded and corresponds to the number of cells in a certain volume. Diluting the blood sample to a sufficient extent for the distance between the cells when passing through the capillary to be greater than the dimension of the cells and capillary ensures that each cell is counted individually. As cells are counted in an absolute volume of the suspension, the number of cells in mm3 of whole blood can be calculated using the dilution factor. The described automated Celloscope cell count method enabled an improved accuracy compared with manual examination by microscopy, while decreasing manual work for the operator. The method allows 50 000 cells to be counted in about 45 seconds, with high accuracy. The Celloscope counter was also equipped with a discriminator, or electrical threshold, which allows only pulses above a certain size to be counted, enabling different blood cells to be counted.
Sources: en.wikipedia.org
HBTU (hexafluorophosphate benzotriazole tetramethyl uronium) is a coupling reagent used in solid phase peptide synthesis. It was introduced in 1978 and shows resistance against racemization. It is used because of its mild activating properties. HBTU is prepared by reaction of hydroxybenzotriazole with TCFH under basic conditions and was assigned to a uronium type structure, presumably by analogy with the corresponding phosphonium salts, which bear a positive carbon atom instead of the phosphonium residue. Later, it was shown by X-ray analysis that salts crystallize as guanidinium rather than the corresponding uronium salts.
=== Cartilage transplants === In 2021, researchers from Swansea University partnered with the Scar Free Foundation to bioprint 3D transplantable cartilage made of human stem cells and plant-based materials to give a 10-year-old girl an ear transplant. This method eliminated the need to retrieve cartilage from elsewhere on the patient's body.
== Application == Knowing the direction of Langer's lines within a specific area of the skin is important for surgical operations, particularly cosmetic surgery. If a surgeon has a choice about where and in what direction to place an incision, they may choose to cut in the direction of Langer's lines. Incisions made parallel to Langer's lines may heal better and produce less scarring than those that cut across. Conversely, incisions perpendicular to Langer's lines have a tendency to pucker and remain obvious, although sometimes this is unavoidable. The orientation of stab wounds relative to Langer's lines can have a considerable impact upon the presentation of the wound. Langer's lines include breast static tension lines, which mark a guide for breast surgery incisions. Keloids are more common when incision is given across Langer's lines. Sometimes the exact direction of the collagen fibers are unknown, because in some regions of the body there are differences between different individuals.
Collagen XVII, previously called BP180, is a transmembrane protein which plays a critical role in maintaining the linkage between the intracellular and the extracellular structural elements involved in epidermal adhesion, identified by Diaz and colleagues in 1990. COL17A1 is the official name of the gene. It encodes the alpha chain of type XVII collagen. Collagen XVII is a transmembrane protein, like collagen XIII, XXIII and XXV. Collagen XVII is a structural component of hemidesmosomes, multiprotein complexes at the dermal-epidermal basement membrane zone that mediate adhesion of keratinocytes to the underlying membrane. It also appears to be a key protein in maintaining the integrity of the corneal epithelium. Mutations in this gene are associated with both generalized atrophic benign and junctional epidermolysis bullosa, as well as recurrent corneal erosions, and expression of this gene is abnormal in various cancers. Two homotrimeric forms of type XVII collagen exist. The full length form is the transmembrane protein. A soluble form, referred to as either ectodomain or LAD-1, is generated by proteolytic processing of the full length form.
Sources: en.wikipedia.org
Curium ion in solution almost always has a +3 oxidation state, the most stable oxidation state for curium. A +4 oxidation state is seen mainly in a few solid phases, such as CmO2 and CmF4. Aqueous curium(IV) is only known in the presence of strong oxidizers such as potassium persulfate, and is easily reduced to curium(III) by radiolysis and even by water itself. The chemical behavior of curium is different from the actinides thorium and uranium, and is similar to americium and many lanthanides. In aqueous solution, the Cm3+ ion is colorless to pale green; Cm4+ ion is pale yellow. The optical absorption of Cm3+ ion contains three sharp peaks at 375.4, 381.2 and 396.5 nm and their strength can be directly converted into the concentration of the ions. The +6 oxidation state has only been reported once in solution in 1978, as the curyl ion (CmO2+2): this was prepared from beta decay of americium-242 in the americium(V) ion 242AmO+2. Failure to get Cm(VI) from oxidation of Cm(III) and Cm(IV) may be due to the high Cm4+/Cm3+ ionization potential and the instability of Cm(V). Curium ions are hard Lewis acids and thus form most stable complexes with hard bases. The bonding is mostly ionic, with a small covalent component. Curium in its complexes commonly exhibits a 9-fold coordination environment, with a tricapped trigonal prismatic molecular geometry.
==== Greater ICE enforcement and deportations ==== Many Democratic and legal organizations have shared warnings about the expansion of immigration enforcement. Rep. Alexandria Ocasio-Cortez shared, "I don't think anyone is prepared for what they just did with ICE. This is not a simple budget increase. It is an explosion—making ICE bigger than the FBI, US Bureau of Prisons, DEA, and others combined. It is setting up to make what's happening now look like child's play. And people are disappearing."
The Montessori Middle School Program completes the Montessori studies for students progressing to the seventh and eighth grades. An interdisciplinary teaching team provides the Montessori Program for multidisciplinary learning to include English Language Arts, mathematics, science and social studies. At the high school level, the student can apply for entry to Biotechnology, Biomedical, Military Academy, Center for the Visual & Performing Arts and/or the Science & Technology Center. Locations:
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.